These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 15779886)
1. Mapping and binding analysis of peptides derived from the tumor-associated antigen survivin for eight HLA alleles. Bachinsky MM; Guillen DE; Patel SR; Singleton J; Chen C; Soltis DA; Tussey LG Cancer Immun; 2005 Mar; 5():6. PubMed ID: 15779886 [TBL] [Abstract][Full Text] [Related]
2. Identification of a promiscuous HLA DR-restricted T-cell epitope derived from the inhibitor of apoptosis protein survivin. Piesche M; Hildebrandt Y; Zettl F; Chapuy B; Schmitz M; Wulf G; Trümper L; Schroers R Hum Immunol; 2007 Jul; 68(7):572-6. PubMed ID: 17584578 [TBL] [Abstract][Full Text] [Related]
3. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin. Hirohashi Y; Torigoe T; Maeda A; Nabeta Y; Kamiguchi K; Sato T; Yoda J; Ikeda H; Hirata K; Yamanaka N; Sato N Clin Cancer Res; 2002 Jun; 8(6):1731-9. PubMed ID: 12060610 [TBL] [Abstract][Full Text] [Related]
4. Immunodominance across HLA polymorphism: implications for cancer immunotherapy. Kim CJ; Parkinson DR; Marincola F J Immunother; 1998 Jan; 21(1):1-16. PubMed ID: 9456431 [TBL] [Abstract][Full Text] [Related]
5. Peptide-pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA-A*0201-binding peptides from the Melan-A/MART-1 self antigen. van Elsas A; van der Burg SH; van der Minne CE; Borghi M; Mourer JS; Melief CJ; Schrier PI Eur J Immunol; 1996 Aug; 26(8):1683-9. PubMed ID: 8765006 [TBL] [Abstract][Full Text] [Related]
6. Identification and functional validation of MHC class I epitopes in the tumor-associated antigen 5T4. Shingler WH; Chikoti P; Kingsman SM; Harrop R Int Immunol; 2008 Aug; 20(8):1057-66. PubMed ID: 18567615 [TBL] [Abstract][Full Text] [Related]
7. Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1. Chaux P; Luiten R; Demotte N; Vantomme V; Stroobant V; Traversari C; Russo V; Schultz E; Cornelis GR; Boon T; van der Bruggen P J Immunol; 1999 Sep; 163(5):2928-36. PubMed ID: 10453041 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of serine-peptidase activity enhances the generation of a survivin-derived HLA-A2-presented CTL epitope in colon-carcinoma cells. Preta G; Marescotti D; Fortini C; Carcoforo P; Castelli C; Masucci M; Gavioli R Scand J Immunol; 2008 Dec; 68(6):579-88. PubMed ID: 19000094 [TBL] [Abstract][Full Text] [Related]
9. Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells. Tsai V; Southwood S; Sidney J; Sakaguchi K; Kawakami Y; Appella E; Sette A; Celis E J Immunol; 1997 Feb; 158(4):1796-802. PubMed ID: 9029118 [TBL] [Abstract][Full Text] [Related]
10. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles. Kawakami Y; Robbins PF; Wang X; Tupesis JP; Parkhurst MR; Kang X; Sakaguchi K; Appella E; Rosenberg SA J Immunol; 1998 Dec; 161(12):6985-92. PubMed ID: 9862734 [TBL] [Abstract][Full Text] [Related]
11. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. Kawakami Y; Eliyahu S; Jennings C; Sakaguchi K; Kang X; Southwood S; Robbins PF; Sette A; Appella E; Rosenberg SA J Immunol; 1995 Apr; 154(8):3961-8. PubMed ID: 7706734 [TBL] [Abstract][Full Text] [Related]
12. Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides. Salgaller ML; Afshar A; Marincola FM; Rivoltini L; Kawakami Y; Rosenberg SA Cancer Res; 1995 Nov; 55(21):4972-9. PubMed ID: 7585538 [TBL] [Abstract][Full Text] [Related]
13. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Brossart P; Stuhler G; Flad T; Stevanovic S; Rammensee HG; Kanz L; Brugger W Cancer Res; 1998 Feb; 58(4):732-6. PubMed ID: 9485028 [TBL] [Abstract][Full Text] [Related]
14. Recognition of HLA-A2-restricted mammaglobin-A-derived epitopes by CD8+ cytotoxic T lymphocytes from breast cancer patients. Jaramillo A; Narayanan K; Campbell LG; Benshoff ND; Lybarger L; Hansen TH; Fleming TP; Dietz JR; Mohanakumar T Breast Cancer Res Treat; 2004 Nov; 88(1):29-41. PubMed ID: 15538043 [TBL] [Abstract][Full Text] [Related]
15. Full-length dominant-negative survivin for cancer immunotherapy. Pisarev V; Yu B; Salup R; Sherman S; Altieri DC; Gabrilovich DI Clin Cancer Res; 2003 Dec; 9(17):6523-33. PubMed ID: 14695157 [TBL] [Abstract][Full Text] [Related]
16. Identification of helper T-cell epitopes that encompass or lie proximal to cytotoxic T-cell epitopes in the gp100 melanoma tumor antigen. Kobayashi H; Lu J; Celis E Cancer Res; 2001 Oct; 61(20):7577-84. PubMed ID: 11606397 [TBL] [Abstract][Full Text] [Related]
17. Identification of a MAGE-2-encoded human leukocyte antigen-A24-binding synthetic peptide that induces specific antitumor cytotoxic T lymphocytes. Tahara K; Takesako K; Sette A; Celis E; Kitano S; Akiyoshi T Clin Cancer Res; 1999 Aug; 5(8):2236-41. PubMed ID: 10473111 [TBL] [Abstract][Full Text] [Related]
18. Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. Implications for peptide-based immunotherapy. Rivoltini L; Loftus DJ; Barracchini K; Arienti F; Mazzocchi A; Biddison WE; Salgaller ML; Appella E; Parmiani G; Marincola FM J Immunol; 1996 May; 156(10):3882-91. PubMed ID: 8621927 [TBL] [Abstract][Full Text] [Related]
19. Identification of a common HLA-A*0201-restricted epitope among SSX family members by mimicking altered peptide ligands strategy. He Y; Mao L; Lin Z; Deng Y; Tang Y; Jiang M; Li W; Jia Z; Wang J; Ni B; Wu Y Mol Immunol; 2008 May; 45(9):2455-64. PubMed ID: 18295890 [TBL] [Abstract][Full Text] [Related]
20. HLA-B35-restricted immune responses against survivin in cancer patients. Reker S; Becker JC; Svane IM; Ralfkiaer E; Straten PT; Andersen MH Int J Cancer; 2004 Mar; 108(6):937-41. PubMed ID: 14712500 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]